Gerresheimer (ETR:GXI) has been given a €74.00 ($91.36) target price by investment analysts at JPMorgan Chase & Co. in a research report issued on Tuesday. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 10.37% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Commerzbank set a €77.00 ($95.06) price objective on shares of Gerresheimer and gave the company a “buy” rating in a research report on Monday, February 5th. Hauck & Aufhaeuser set a €55.00 ($67.90) price objective on shares of Gerresheimer and gave the company a “sell” rating in a research report on Tuesday, February 6th. Independent Research set a €74.00 ($91.36) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research report on Thursday, January 25th. Goldman Sachs set a €68.00 ($83.95) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research report on Thursday, January 25th. Finally, Berenberg Bank set a €78.00 ($96.30) price objective on shares of Gerresheimer and gave the company a “buy” rating in a research report on Friday, March 9th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Gerresheimer presently has an average rating of “Hold” and an average price target of €69.64 ($85.97).

How to Become a New Pot Stock Millionaire

Shares of Gerresheimer (GXI) opened at €67.05 ($82.78) on Tuesday. The firm has a market cap of $2,100.00 and a price-to-earnings ratio of 20.89. Gerresheimer has a 52-week low of €59.97 ($74.04) and a 52-week high of €78.25 ($96.60).

ILLEGAL ACTIVITY WARNING: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/gerresheimer-gxi-given-a-74-00-price-target-at-jpmorgan-chase-co/1954737.html.

About Gerresheimer

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.